| Revista: | Belize journal of medicine |
| Base de datos: | PERIÓDICA |
| Número de sistema: | 000418449 |
| ISSN: | 2225-8116 |
| Autores: | Agüero, María Susana1 |
| Instituciones: | 1Hospital Ramón Sarda, Buenos Aires. Argentina |
| Año: | 2012 |
| Periodo: | Feb |
| Volumen: | 1 |
| Número: | 2 |
| Paginación: | 5-9 |
| País: | Belice |
| Idioma: | Inglés |
| Tipo de documento: | Artículo |
| Enfoque: | Analítico |
| Resumen en inglés | Fetal nuchal translucency thickness (NT) at 11–13+6 weeks scan has been combined with maternal age to provide an effective method of screening for trisomy 21; for an invasive testing rate of 5%, about 75% of trisomic pregnancies can be identified. When maternal serum free ß-human chorionic gonadotropin (ß-hCG) and pregnancy-associated plasma protein-A (PAPP-A) at 11–13+6 weeks are also taken into account, the detection rate of chromosomal defects is about 85–90%.It was found that in 60–70% of fetuses with trisomy 21, the nasal bone is not visible in the 11–13+6 weeks scan and examination of the nasal bone can increase screening detection rate by the first trimester scan and serum biochemistry to more than 95%. In addition to its role in the assessment of risk for trisomy 21, increased nuchal translucency thickness can also identify a high proportion of other chromosomal defects and is associated with major abnormalities of the heart and great arteries, and a wide range of genetic syndromes |
| Disciplinas: | Medicina |
| Palabras clave: | Ginecología y obstetricia, Diagnóstico, Genética, Ultrasonido, Tamizaje, Anomalías cromosómicas, Translucidez, Trisomía 21, Gonadotropina coriónica humana (hCG), Amniocentesis |
| Keyword: | Gynecology and obstetrics, Diagnosis, Genetics, Ultrasound, Screening, Chromosomal abnormalities, Translucency, Trisomy 21, Human chorionic gonadotropin (hCG), Amniocentesis |
| Texto completo: | Texto completo (Ver PDF) |
